JOHNSON & JOHNSON — Director's Dealing 2018

Jul 12, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2018-07-02

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	63042.3255	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (Right to Buy)	$72.5400	2023-01-13	Common Stock (76923.0000)		Direct
Employee Stock Options (Right to Buy)	$90.4400	2024-02-09	Common Stock (59397.0000)		Direct
Employee Stock Options (Right to Buy)	$100.0600	2025-02-09	Common Stock (58504.0000)		Direct
Employee Stock Options (Right to Buy)	$101.8700	2026-02-08	Common Stock (56471.0000)		Direct
Employee Stock Options (Right to Buy)	$115.6700	2027-02-13	Common Stock (43712.0000)		Direct
Employee Stock Options (Right to Buy)	$129.5100	2028-02-11	Common Stock (43391.0000)		Direct
Restricted Share Units	$		Common Stock (48312.0000)		Direct
Restricted Share Units	$		Common Stock (8529.0000)		Direct
Restricted Share Units	$		Common Stock (2177.0000)		Direct
Restricted Share Units	$		Common Stock (7724.0000)		Direct

Footnotes

F1: Vested and exercisable one day after the third anniversary of the date of the grant.

F2: Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.